

Alex Serna<sup>1</sup>, Victor Rivas<sup>1</sup>, Joanna Kaplan<sup>1</sup>, Carina Gonzalez<sup>1</sup>, Amanda Crofton<sup>1</sup>, Jalena Wouters<sup>1</sup>, Allison Bradbury<sup>2</sup>, Heather Flanagan-Steet<sup>3</sup>, Joshua Stern<sup>1</sup> <sup>1</sup>School of Veterinary Medicine, University of California, Davis, <sup>2</sup>Abigail Wexner Research Institute Nationwide Children's Hospital, <sup>3</sup>Greenwood Genetic Center

### Introduction

- MLII is an autosomal recessive lysosomal storage disorder caused by a GNPTAB mutation, affecting infant to juvenile children
- The mutation results in a GlcNAc-phosphotransferase defect, which prevents normal trafficking of acid hydrolases into lysosomes
- Clinical presentation includes:
- Skeletal deformities
- Neurologic lesions
- Heart valve thickening
- High mortality rate (MST= ~5 years)
- Poorly characterized cardiovascular disease leading to fulminant congestive heart failure
- A novel, naturally occurring feline MLII model has been identified
- Autosomal recessive MOI
- Pathogenic GNPTAB nonsense mutation • Exon 13 c.2644C>T; p.Gln882\*
- Cats display cardiovascular phenotypes that recapitulate human MLII with variable presence of congenital cardiac defects
- Studies interrogating the genotype-phenotype relationship of feline MLII promise continued advancements in targeted novel drug therapies in humans
- Study aims include expanding the MLII cat colony and further characterizing the disease in cats for human translational use



illustration of GNPTAB gene body and downstream protein interactions. Black arrow represents positioning of previously identified GNPTAB MLII-associated mutation in cats. (B) Illustration of MLII molecular pathogenesis.

## Hypothesis

Additional cardiovascular phenotypes observed in MLII-affected cats are explained by compound pathogenic mutations with implicated changes to the mitral and aortic valves, leading to volume overload and congestive heart failure. These findings will mimic those observed in children with MLII and support use of the feline MLII colony in studies aiming to alter cardiovascular outcomes.

# Cardiovascular Manifestations of Mucolipidosis II: A Translational Feline Model

